Medtech Funding News: Science37’s Latest Raise and 2026 Trends

Medtech funding news is buzzing as Science37 secures fresh capital to fuel its decentralized clinical trial platform amid a surging market.

Here’s a quick overview:

• Science37 raised $50 million in Series D funding led by Emerson Collective, bringing total funding to over $200 million.
• This reflects broader 2026 medtech trends: M&A deals up 25% year-over-year, with AI-driven diagnostics and robotics attracting $12.5 billion in investments.
• Key drivers include precision medicine breakthroughs and regulatory tailwinds from FDA’s streamlined approvals.

What is Science37 and Why Does This Funding Matter?

Imagine running clinical trials without patients traveling to sites—Science37 makes that possible through its DEcentralized Science (DECS) platform. Founded in 2016, the company connects patients, providers, and sponsors via software that handles everything from eConsent to remote monitoring.

This latest medtech funding news isn’t just another round; it’s a vote of confidence in decentralized trials as the future of drug development. With patient recruitment delays costing pharma $1.5 million per day on average (per Tufts Center for the Study of Drug Development), Science37’s tech slashes those timelines by up to 40%. If you’re a startup founder or investor, this raise signals where capital flows: scalable platforms solving real pain points in healthcare delivery.

Quick Answer: Why invest in medtech like Science37 now? Remote trials reduce costs by 30-50% and boost diversity, aligning with FDA mandates for inclusive data.

Breaking Down the $50M Raise

Q: What are the details of Science37’s funding?
A: In March 2026, Science37 closed a $50 million Series D extension led by Emerson Collective, with participation from existing backers like Andreessen Horowitz and B Capital. This pushes their valuation past $500 million and funds platform expansions into AI-powered patient matching.

Details matter in medtech funding news:

• Use of funds: Enhancing AI algorithms for trial predictions and global scaling.
• Timing: Announced amid a 22% uptick in medtech VC deals quarter-over-quarter.
• Strategic angle: Partnerships with Big Pharma like Pfizer deepen, positioning Science37 for acquisitions.

Unlike traditional raises, this one emphasizes outcomes—Science37 reports 3x faster enrollment in ongoing trials. For context, National Institutes of Health data shows decentralized models improve retention by 25%.

Medtech Funding News: 2026 Landscape

Medtech funding news in 2026 paints a bullish picture, with $28.4 billion invested globally—up 18% from 2025. AI integration and robotics dominate, but let’s break it down.

Hottest Sectors

• AI Diagnostics: $6.2B raised; think PathAI’s imaging tools detecting cancer 20% faster.
• Robotics/Surgery: $4.8B; Intuitive Surgical-inspired startups like Vicarious Surgical.
• Precision Medicine: $3.9B; Genomics firms leveraging CRISPR advancements.

Why it matters: Investors chase ROI from reimbursable innovations. Medicare’s expanded coverage for AI tools (per CMS guidelines) de-risks bets.

Investor Trends

VCs like Sequoia and Khosla Ventures prioritize “capital-efficient” startups—those hitting $5M ARR with <50 employees. Corporate VCs from Medtronic and Johnson & Johnson scooped 35% of deals.

Edge case: Bootstrapped medtechs struggle without IP moats; pair hardware with SaaS for hybrid appeal.

Step-by-Step Action Plan for Medtech Startups Seeking Funding

New to medtech funding news? Here’s your beginner-friendly roadmap. I’ve advised dozens of founders—follow this, and you’ll pitch like a pro.

1. Validate Your Idea (Weeks 1-4): Build an MVP and test with 50 beta users. Metric: 70% satisfaction rate. Tool: Use free FDA 510(k) databases for clearance paths.
2. Craft Your Deck (Week 5): 10 slides max—problem, solution, traction, TAM ($1.2T medtech market), team, ask. Include “unfair advantages” like patents.
3. Target Investors (Weeks 6-8):
   • Angels/accelerators first (Y Combinator Bio, Rock Health).
   • Then VCs: Pitch 50, expect 5 meetings.
   • Warm intros via LinkedIn (search “medtech partner [firm]”).
4. Demo Day Prep (Week 9): Rehearse 5x. Answer: “What’s your go-to-market?” with payer pilots.
5. Close the Round (Weeks 10-12): Negotiate 18-24 month runway. Use SAFEs for speed.

Checklist:

• IP filed?
• Clinical data (even pilot)?
• Regulatory roadmap?
• Financial model (3-year projection)?

If bootstrapping, aim for grants like SBIR from NIH.

Comparison: Top Medtech Funding Sources in 2026

Funding Source	Pros	Cons	Best For	Avg. Check Size
VC Firms (e.g., Khosla Ventures)	Large sums, networks	Equity dilution (20-30%), long process	Series A+ with traction	$10-50M
Corporate VC (Medtronic Ventures)	Strategic partnerships	Slower decisions	Synergistic tech	$5-20M
Accelerators (Rock Health)	Mentorship, $250K quick	Competitive (1% acceptance)	Early seed	$100K-1M
Government Grants (NIH SBIR)	Non-dilutive	Paperwork-heavy	Basic research	$150K-1.5M
Crowdfunding (e.g., StartEngine)	Validates market	Caps at $5M/year	Consumer medtech	$500K-2M

This table simplifies choices—pick based on stage and dilution tolerance.

Common Mistakes in Medtech Funding + Fixes

From experience, here’s what trips founders up in medtech funding news chases:

• Mistake 1: Ignoring Regs – Pitching without FDA path. Fix: Map 510(k) or De Novo early; consult FDA’s guidance portal.
• Mistake 2: Weak Traction – No pilots. Fix: Run hospital betas; aim for LOIs from 3 providers.
• Mistake 3: Overvaluing – Asking $20M pre-money at seed. Fix: Benchmark via PitchBook (avg. seed: $8M post).
• Mistake 4: Solo Pitches – No co-founder balance. Fix: Tech + biz duo shines.
• Edge Case: Overseas founders—fix visa issues pre-pitch with E-2/STTR paths.

What I’d do: Stress-test your model with 10 advisors before deck one.

Key Takeaways

• Science37’s $50M raise highlights decentralized trials as a medtech funding news hotspot.
• 2026 sees $28B+ in investments, led by AI and robotics.
• Prioritize IP, pilots, and regs for investor appeal.
• Use hybrid funding: Grants + VC for non-dilutive starts.
• Avoid overvaluation; benchmark against peers.
• Corporate VCs offer partnerships but move slower.
• Track FDA updates for de-risking.
• Build capital-efficient teams for faster closes.

Conclusion

Medtech funding news like Science37’s raise shows a vibrant ecosystem ripe for innovators solving healthcare’s biggest hurdles. You’ve got the trends, plan, and pitfalls to avoid—now audit your startup against this blueprint. Your next step? Refine that deck and book 5 investor coffees this week. Success favors the prepared.

About the Author

Ava Gardner
Healthcare funding strategist with 10+ years advising medtech startups on raises and exits. Previously at Rock Health accelerator.
Disclosure: This article is informational, not professional advice. Consult experts for your situation.

Frequently Asked Questions